Belite Bio, Inc (BLTE) Discusses Prelaunch Strategy and Commercial Opportunity for Tinlarebant in Stargardt Disease Type 1 Transcript

SA Transcripts 162.07K Followers Follow Belite Bio, Inc ( BLTE ) Discusses Prelaunch Strategy and Commercial Opportunity for Tinlarebant in Stargardt Disease Type 1 September 2, 2026 8:00 AM EDT Company Participants Julie Fallon Yu-Hsin Lin - Chairman of the Board of Directors & CEO Hendrik Scholl - Chief Medical Officer Kelly Kilpatrick Conference Call Participants Michel Michaelides Paul Bernstein Judah Frommer - Morgan Stanley, Research Division Tazeen Ahmad - BofA Securities, Research Division Steven Seedhouse - Cantor Fitzgerald & Co., Research Division Presentation Operator Ladies and gentlemen, thank you for joining us, and welcome to the Belite Bio 2026 Commercial Day. [Operator Instructions]. I will now hand the conference over to Julie Fallon. Please go ahead. Julie Fallon Good morning, everyone, and welcome to the Belite Bio Commercial Day. Before we begin, let me point out that we will be making forward-looking statements that are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and actual results may differ materially. We encourage you to consult the risk factors discussed in our SEC filings for additional detail. Our goals for today are to provide you with an overview of the current diagnosis path and treatment paradigm for Stargardt disease type 1. How Stargardt impacts people's day-to-day lives, the significant unmet need for treatment and Belite Bio's commercial preparedness strategy. We have a full agenda. So with that, let me turn the call over to Dr. Lin, Belite Bio's Chairman and CEO, for opening remarks. Dr. Lin? Yu-Hsin Lin Chairman of the Board of Directors & CEO Good morning, everyone, and thank you for joining us for Belite Bio's Commercial Day. We are pleased to have the opportunity to share how we are preparing for what we believe could be a transformational next chapter for our company and for patients living with Stargardt disease type 1. At Belite Bio, our